Nizatidine is a histamine H2-receptor antagonist used to reduce stomach acid production and treat conditions such as peptic ulcer disease and gastroesophageal reflux disease (GERD). It was developed in the 1980s and approved for medical use in the United States in 1988. Its history is notable for its effectiveness in suppressing gastric acid secretion with a relatively favorable safety profile compared to earlier acid-reducing drugs. Nizatidine works by blocking H2 receptors in the stomach lining, thereby decreasing acid production and promoting ulcer healing. After its introduction, it became part of standard therapy options for acid-related disorders, though its use has declined in some regions due to the widespread availability of proton pump inhibitors.
BRAND NAMES
Axid is a prescription histamine-2 (H2) blocker
Axid AR is an over-the-counter H2 blocker
Axid Pulvules is a prescription histamine H2-receptor antagonist.
MECHANISM OF ACTION
Nizatidine is a histamine H2-receptor antagonist. It works by selectively blocking H2 receptors on the parietal cells of the stomach. Normally, histamine binds to these receptors and stimulates the production of gastric acid. By inhibiting this action, nizatidine reduces both basal (resting) and stimulated secretion of stomach acid, including acid released in response to food, gastrin, and other stimuli.
PHARMACOKINETICS
Absorption
Nizatidine is rapidly and almost completely absorbed after oral administration. Peak plasma concentrations are typically reached within 0.5 to 3 hours. The bioavailability is high (about 70–100%), and food has little to no significant effect on the extent of absorption, although it may slightly delay the time to peak concentration.
Distribution
Nizatidine has a relatively low volume of distribution, approximately 0.8–1.5 L/kg, indicating that it is largely confined to the extracellular fluid and does not extensively distribute into tissues.
Metabolism
Nizatidine undergoes minimal hepatic metabolism. A small portion of the drug is biotransformed in the liver into inactive metabolites, primarily through oxidation and conjugation pathways. However, the majority of the administered dose is excreted unchanged, indicating that hepatic metabolism plays a minor role in its overall elimination.
Elimination
Nizatidine is eliminated primarily through the kidneys, with about 60–70% of the dose excreted unchanged in urine. A smaller fraction is eliminated as inactive metabolites. The drug has a half-life of approximately 1 to 2 hours, and its clearance is significantly reduced in patients with renal impairment, requiring dose adjustment in such cases.
PHARMACODYNAMICS
Nizatidine is a competitive, reversible histamine H2-receptor antagonist that reduces gastric acid secretion. It acts by selectively blocking H2 receptors on gastric parietal cells, thereby inhibiting both basal and stimulated acid secretion induced by histamine, gastrin, and acetylcholine. This leads to decreased gastric acidity and volume, increased gastric pH, and promotion of healing in acid-related disorders such as peptic ulcers and gastroesophageal reflux disease (GERD).
ADMINISTRATION
Nizatidine is administered orally in capsule or liquid form. It may be taken with or without food, as food does not significantly affect its absorption. It is commonly prescribed once or twice daily depending on the indication, such as peptic ulcer disease or GERD. Patients are advised to take it consistently at the same times each day to maintain effective acid suppression and improve symptom control.
DOSAGE AND STRENGTH
For adults, the typical dose is 150 mg twice daily or 300 mg once daily for active duodenal ulcer or GERD. For maintenance therapy, lower doses such as 150 mg once daily (at bedtime) may be used. Dosage adjustment is required in patients with renal impairment, as drug clearance is reduced. Pediatric dosing is less commonly used and should be determined by a physician based on weight and clinical condition.
DRUG INTERACTIONS
Nizatidine has relatively few clinically significant drug interactions. Unlike some other H2 blockers, it does not strongly inhibit hepatic cytochrome P450 enzymes. However, it may alter the absorption of drugs that require acidic gastric pH for absorption, such as ketoconazole or itraconazole. Alcohol may increase gastric irritation but does not directly interact with nizatidine’s mechanism.
FOODINTERACTIONS
Nizatidine does not have significant food interactions and can be taken with or without meals. Food may slightly delay absorption but does not reduce overall effectiveness.
CONTRAINDICATIONS
Nizatidine is contraindicated in patients with known hypersensitivity to nizatidine or other H2-receptor antagonists. Caution is advised in patients with severe renal impairment, where dose adjustment is necessary.
SIDE EFFECTS
Headache
Dizziness
Fatigue
Nausea
Vomiting
Abdominal pain
Diarrhea
Constipation
Skin rash or itching
Mild drowsiness or insomnia (rare)
OVER DOSAGE
Nizatidine overdose is uncommon and usually has a wide safety margin. However, excessive intake may lead to symptoms such as confusion, dizziness, drowsiness, headache, nausea, vomiting, and gastrointestinal discomfort. In severe cases, especially in patients with renal impairment, there may be increased central nervous system effects like agitation or disorientation due to drug accumulation.
TOXICITY
Nizatidine toxicity is rare and usually associated with overdose or severe renal impairment. Potential effects include confusion, agitation, gastrointestinal disturbances, and in severe cases, CNS symptoms such as dizziness or drowsiness. Because it is primarily eliminated by the kidneys, accumulation can occur in renal dysfunction, increasing the risk of adverse effects. Severe toxicity is uncommon due to its wide safety margin.
